This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the official electronic version on GPO’s govinfo.gov.
The documents posted on this site are XML renditions of published Federal Register documents. Each document posted on the site includes a link to the corresponding official PDF file on govinfo.gov. This prototype edition of the daily Federal Register on FederalRegister.gov will remain an unofficial informational resource until the Administrative Committee of the Federal Register (ACFR) issues a regulation granting it official legal status. For complete information about, and access to, our official publications and services, go to About the Federal Register on NARA's archives.gov.
The OFR/GPO partnership is committed to presenting accurate and reliable regulatory information on FederalRegister.gov with the objective of establishing the XML-based Federal Register as an ACFR-sanctioned publication in the future. While every effort has been made to ensure that the material on FederalRegister.gov is accurately displayed, consistent with the official SGML-based PDF version on govinfo.gov, those relying on it for legal research should verify their results against an official edition of the Federal Register. Until the ACFR grants it official status, the XML rendition of the daily Federal Register on FederalRegister.gov does not provide legal notice to the public or judicial notice to the courts.
Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) has determined that the 19 drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Olivia Pritzlaff, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 6308, Silver Spring, MD 20993-0002, 301-796-3601.End Further Info End Preamble Start Supplemental Information
In 1984, Congress enacted the Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417) (the 1984 amendments), which authorized the approval of duplicate versions of drug products approved under an ANDA procedure. ANDA sponsors must, with certain exceptions, show that the drug for which they are seeking approval contains the same active ingredient in the same strength and dosage form as the “listed drug,” which is a version of the drug that was previously approved. Sponsors of ANDAs do not have to repeat the extensive clinical testing otherwise necessary to gain approval of a new drug application (NDA). The only clinical data required in an ANDA are data to show that the drug that is the subject of the ANDA is bioequivalent to the listed drug.
The 1984 amendments include what is now section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355(j)(7)), which requires FDA to publish a list of all approved drugs. FDA publishes this list as part of the “Approved Drug Products With Therapeutic Equivalence Evaluations,” which is generally known as the “Orange Book.” Under FDA regulations, a drug is withdrawn from the list if the agency withdraws or suspends approval of the drug's NDA or ANDA for reasons of safety or effectiveness, or if FDA determines that the listed drug was withdrawn from sale for reasons of safety or effectiveness (21 CFR 314.162).
Under § 314.161(a) (21 CFR 314.161(a)), the agency must determine whether a listed drug was withdrawn from sale for reasons of safety or effectiveness: (1) Before an ANDA that refers to that listed drug may be approved; (2) whenever a listed drug is voluntarily withdrawn from sale and ANDAs that refer to the listed drug have been approved; and (3) when a person petitions for such a determination under 21 CFR 10.25(a) and 10.30. Section 314.161(d) provides that if FDA determines that a listed drug was withdrawn from sale for reasons of safety or effectiveness, the agency will initiate proceedings that could result in the withdrawal of approval of the ANDAs that refer to the listed drug.
FDA has become aware that the drug products listed in the table in this document are no longer being marketed. (As requested by the applicants, FDA withdrew approval of NDA 20-225 for IMDUR (isosorbide mononitrate) Extended-Release Tablets in the Federal Register of February 11, 2009 (74 FR 6896) and NDA 11-556 for ANTURANE (sulfinpyrazone) Tablets and Capsules, NDA 15-500 for TOLINASE (tolazamide) Tablets, NDA 18-285 for VISKEN (pindolol) Tablets, NDA 20-137 for DEMADEX (torsemide) Injection, and NDA 20-154 for VIDEX (didanosine) Chewable Tablets in the Federal Register of May 19, 2009 (74 FR 23407)).
|NDA 9-149||THORAZINE (chlorpromazine hydrochloride (HCI)) Injection, 25 milligrams (mg)/milliliter (mL)||GlaxoSmithKline, 2301 Renaissance Blvd., King of Prussia, PA 19406|
|NDA 9-149||THORAZINE (chlorpromazine HCl) Oral Concentrate, 30 mg/mL and 100 mg/mL||Do.|
|NDA 9-149||THORAZINE (chlorpromazine HCl) Oral Syrup, 10 mg/5 mL||Do.|
|NDA 9-149||THORAZINE (chlorpromazine) Suppositories, 25 mg and 100 mg||Do.|
|NDA 11-552||STELAZINE (trifluoperazine HCl) Tablets, Equivalent to (EQ) 1 mg base, EQ 2 mg base, EQ 5 mg base, and EQ 10 mg base||Do.|
|NDA 11-556||ANTURANE (sulfinpyrazone) Tablet, 100 mg||Novartis Pharmaceuticals Corp., One Health Plaza, East Hanover, NJ 07963|
|NDA 11-556||ANTURANE (sulfinpyrazone) Capsule, 200 mg||Do.|
|NDA 12-940||ISORDIL (isosorbide dinitrate) Sublingual Tablets, 2.5 mg, 5 mg, and 10 mg||Biovail Pharmaceuticals, Inc., 700 Route 202-206 North, Bridgewater, NJ 08807-0980|
|NDA 15-500||TOLINASE (tolazamide) Tablets, 100 mg, 250 mg, and 500 mg||Pfifzer, Inc., 235 East 42d St., New York, NY 10017|
|Start Printed Page 28256|
|NDA 18-154||LONITEN (minoxidil) Tablets, 2.5 mg and 10 mg||Pharmacia & Upjohn Co., c/o Pfizer, Inc.|
|NDA 18-285||VISKEN (pindolol) Tablets, 5 mg and 10 mg||Novartis Pharmaceuticals Corp.|
|NDA 18-445||DOLOBID (diflunisal) Tablets, 250 mg and 500 mg||Merck & Co., Inc., Sunneytown Pike, P.O. Box 4, BLA-20, West Point, PA 19486|
|NDA 19-661||CYTOVENE IV (ganciclovir sodium) Injection, EQ 500 mg base/vial||Roche Laboratories, Inc., 340 Kingsland St., Nutley, NJ 07110-1199|
|NDA 20-027||CARDIZEM (diltiazem HCl) Injection, 5 mg/mL and 25 mg/vial||Biovail Pharmaecuticals, Inc.|
|NDA 20-137||DEMADEX (torsemide) Injection, 20 mg/2 mL (10 mg/mL) and 50 mg/5 mL (10 mg/mL)||Roche Laboratories, Inc.|
|NDA 20-154||VIDEX (didanosine) Chewable Tablets, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg||Bristol-Myers Squibb Co., P.O. Box 5100, Wallingford, CT 06492-7660|
|NDA 20-225||IMDUR (isosorbide mononitrate) Extended-Release Tablets, 30 mg, 60 mg, and 120 mg||Schering Corp., 2000 Galloping Hill Rd., Kenilworth, NJ 07033|
|NDA 21-238||KYTRIL (granisetron HCl) Oral Solution, EQ 2 mg base/10 mL||Roche Laboratories, Inc.|
|NDA 21-301||LEVOXYL (levothyroxine sodium) Tablet, 0.3 mg||King Pharmaceuticals, Inc., 501 Fifth St., Bristol, TN 37620|
FDA has reviewed its records and, under § 314.161, has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. Accordingly, the agency will continue to list the drug products listed in this document in the “Discontinued Drug Product List” section of the Orange Book. The “Discontinued Drug Product List” identifies, among other items, drug products that have been discontinued from marketing for reasons other than safety or effectiveness.
Approved ANDAs that refer to the NDAs listed in this document are unaffected by the discontinued marketing of the products subject to those NDAs. Additional ANDAs that refer to these products may also be approved by the agency if they comply with relevant legal and regulatory requirements. If FDA determines that labeling for these drug products should be revised to meet current standards, the agency will advise ANDA applicants to submit such labeling.Start Signature
Dated: June 5, 2009.
Associate Commissioner for Policy and Planning.
[FR Doc. E9-14000 Filed 6-12-09; 8:45 am]
BILLING CODE 4160-01-S